[18F]MK-9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users

Addiction Biology

Volumn 20, Issue 2, 2015, Pages 357-367

  Ceccarini, Jenny ^a   Kuepper, Rebecca ^b   Kemels, Dieter ^a   Van Os, Jim ^b,c   Henquet, Cécile ^b,d   Van Laere, Koen ^a,e  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d PsyQ Heerlen   (Netherlands)

^e UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

cannabis addiction; CB1 receptor; PET; 18F MK 9470

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABIS; MK 9470 F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; MK-9470; PYRIDINE DERIVATIVE;

ADULT; ARTICLE; BRAIN LEVEL; CANNABIS ADDICTION; CAUDATE NUCLEUS; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FRONTAL LOBE; GLOBUS PALLIDUS; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; INSULA; MALE; MEASUREMENT; NUCLEUS ACCUMBENS; OCCIPITAL LOBE; PARIETAL LOBE; PONS; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRIORITY JOURNAL; PUTAMEN; TEMPORAL LOBE; THALAMUS; ADAPTATION; BRAIN; CASE CONTROL STUDY; DIAGNOSTIC USE; METABOLISM; SCINTISCANNING; YOUNG ADULT;

ADAPTATION, PHYSIOLOGICAL; ADULT; BRAIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MARIJUANA ABUSE; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RADIOPHARMACEUTICALS; RECEPTOR, CANNABINOID, CB1; YOUNG ADULT;

EID: 84922999906     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/adb.12116     Document Type: Article

References (52)

1. American Psychiatry Association (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th edn, text rev. Washington, DC: American Psychiatry Association.
2. Braida D, Iosue S, Pegorini S, Sala M, (2004) Delta9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats. Eur J Pharmacol 506: 63-69.
3. Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Vogt LJ, Sim-Selley LJ, (1999) Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J Neurochem 73: 2447-2459.
4. Breivogel CS, Scates SM, Beletskaya IO, Lowery OB, Aceto MD, Martin BR, (2003) The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors. Eur J Pharmacol 459: 139-150.
5. 18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci U S A 104: 9800-9805.
6. Ceccarini J, Casteels C, Koole M, Bormans G, Van Laere K, (2013a) Transient changes in the endocannabinoid system after acute and chronic ethanol exposure and abstinence in the rat: a combined PET and microdialysis study. Eur J Nucl Med Mol Imaging 40: 1582-1594.
7. Ceccarini J, De Hert M, Van Winkel R, Peuskens J, Bormans G, Kranaster L, Enning F, Koethe D, Leweke MF, Van Laere K, (2013b) Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. Neuroimage 79C: 304-312.
8. Ceccarini J, Hompes T, Verhaegen H, Bormans G, Claes S, Van Laere K, (2009) Changes in cerebral type 1 cannabinoid receptor (CB1R) availability in ethanol dependent patients after binge drinking and abstinence. J Nucl Med 50 (Suppl. 2): 1290.
9. Clapper JR, Mangieri RA, Piomelli D, (2009) The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology 56 (Suppl. 1): 235-243.
10. Cooper ZD, Haney M, (2008) Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor. Addict Biol 13: 188-195.
11. 18F]MK-9470. J Mol Neurosci 42: 162-167.
12. Gérard N, Pieters G, Goffin K, Bormans G, Van Laere K, (2011) Brain type 1 cannabinoid receptor availability in patients with anorexia and bulimia nervosa. Biol Psychiatry 70: 777-784.
13. Glass M, Dragunow M, Faull RL, (1997) Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77: 299-318.
14. Gonzalez S, Cebeira M, Fernandez-Ruiz J, (2005) Cannabinoid tolerance and dependence: a review of studies in laboratory animals. Pharmacol Biochem Behav 81: 300-318.
15. Hall W, Degenhardt L, (2009) Adverse health effects of non-medical cannabis use. Lancet 374: 1383-1391.
16. Henquet C, Di Forti M, Morrison P, Kuepper R, Murray RM, (2008) Gene-environment interplay between cannabis and psychosis. Schizophr Bull 34: 1111-1121.
17. Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C, Pike VW, Volkow ND, Huestis MA, Innis RB, (2012a) Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry 17: 642-649.
18. Hirvonen J, Zanotti-Fregonara P, Umhau JC, George DT, Rallis-Frutos D, Lyoo CH, Li CT, Hines CS, Sun H, Terry GE, Morse C, Zoghbi SS, Pike VW, Innis RB, Heilig M, (2012b) Reduced cannabinoid CB(1) receptor binding in alcohol dependence measured with positron emission tomography. Mol Psychiatry 18: 916-921.
19. Hoffman AF, Lupica CR, (2013) Synaptic targets of delta9-tetrahydrocannabinol in the central nervous system. Cold Spring Harb Perspect Med 3: a012203.
20. Hoffman AF, Oz M, Caulder T, Lupica CR, (2003) Functional tolerance and blockade of long-term depression at synapses in the nucleus accumbens after chronic cannabinoid exposure. J Neurosci 23: 4815-4820.
21. Huestis MA, Boyd SJ, Heishman SJ, Preston KL, Bonnet D, Le Fur G, Gorelick DA, (2007) Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl) 194: 505-515.
22. Iversen L, (2003) Cannabis and the brain. Brain 126: 1252-1270.
23. Kalivas PW, McFarland K, (2003) Brain circuitry and the reinstatement of cocaine-seeking behavior. Psychopharmacology (Berl) 168: 44-56.
24. Maldonado R, (2002) Study of cannabinoid dependence in animals. Pharmacol Ther 95: 153-164.
25. Martin BR, Sim-Selley LJ, Selley DE, (2004) Signaling pathways involved in the development of cannabinoid tolerance. Trends Pharmacol Sci 25: 325-330.
26. Mechoulam R, (1970) Marihuana chemistry. Science 168: 1159-1166.
27. Murray RM, Morrison PD, Henquet C, Di Forti M, (2007) Cannabis, the mind and society: the hash realities. Nat Rev Neurosci 8: 885-895.
28. Oviedo A, Glowa J, Herkenham M, (1993) Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res 616: 293-302.
29. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA, (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacol Rev 62: 588-631.
30. Rodriguez de Fonseca F, Gorriti MA, Fernandez-Ruiz JJ, Palomo T, Ramos JA, (1994) Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment. Pharmacol Biochem Behav 47: 33-40.
31. Romero J, Berrendero F, Manzanares J, Perez A, Corchero J, Fuentes JA, Fernández-Ruiz JJ, Ramos JA, (1998) Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta9-tetrahydrocannabinol. Synapse 30: 298-308.
32. Romero J, Garcia-Palomero E, Castro JG, Garcia-Gil L, Ramos JA, Fernández-Ruiz JJ, (1997) Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Brain Res Mol Brain Res 46: 100-108.
33. Sanabria-Bohorquez SM, Hamill TG, Goffin K, De Lepeleire I, Bormans G, Burns HD, Van Laere K, (2010) Kinetic analysis of the cannabinoid-1 receptor PET tracer [(18)F]MK-9470 in human brain. Eur J Nucl Med Mol Imaging 37: 920-933.
34. Schlosburg JE, Carlson BL, Ramesh D, Abdullah RA, Long JZ, Cravatt BF, Lichtman AH, (2009) Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice. AAPS J 11: 342-352.
35. Sim LJ, Hampson RE, Deadwyler SA, Childers SR, (1996) Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain. J Neurosci 16: 8057-8066.
36. Sim-Selley LJ, (2003) Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 15: 91-119.
37. Sim-Selley LJ, Martin BR, (2002) Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxaz inyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. J Pharmacol Exp Ther 303: 36-44.
38. Sim-Selley LJ, Schechter NS, Rorrer WK, Dalton GD, Hernandez J, Martin BR, Selley DE, (2006) Prolonged recovery rate of CB1 receptor adaptation after cessation of long-term cannabinoid administration. Mol Pharmacol 70: 986-996.
39. Terry G, Liow JS, Chernet E, Zoghbi SS, Phebus L, Felder CC, Tauscher J, Schaus JM, Pike VW, Halldin C, Innis RB, (2008) Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents. Neuroimage 41: 690-698.
40. Thie JA, Hubner KF, Isidoro FP, Smith GT, (2007) A weight index for the standardized uptake value in 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography. Mol Imaging Biol 9: 91-98.
41. United Nations Office on Drugs and Crime (UNODC) (2013) World Drug Report.
42. van der Stelt M, Di Marzo V, (2003) The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 480: 133-150.
43. Van Laere K, Casteels C, Dhollander I, Goffin K, Grachev I, Bormans G, Vandenberghe W, (2010) Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo. J Nucl Med 51: 1413-1417.
44. Van Laere K, Casteels C, Lunskens S, Goffin K, Grachev ID, Bormans G, Vandenberghe W, (2012) Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo. Neurobiol Aging 33: 620-628.
45. Van Laere K, Goffin K, Bormans G, Casteels C, Mortelmans L, de Hoon J, Grachev I, Vandenbulcke M, Pieters G, (2009) Relationship of type 1 cannabinoid receptor availability in the human brain to novelty-seeking temperament. Arch Gen Psychiatry 66: 196-204.
46. Van Laere K, Goffin K, Casteels C, Dupont P, Mortelmans L, de Hoon J, Bormans G, (2008) Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [(18)F]MK-9470 PET. Neuroimage 39: 1533-1541.
47. Van Laere K, Nuttin B, Gabriels L, Dupont P, Rasmussen S, Greenberg BD, Cosyns P, (2006) Metabolic imaging of anterior capsular stimulation in refractory obsessive-compulsive disorder: a key role for the subgenual anterior cingulate and ventral striatum. J Nucl Med 47: 740-747.
48. Villares J, (2007) Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain. Neuroscience 145: 323-334.
49. Weinstein AM, Gorelick DA, (2011) Pharmacological treatment of cannabis dependence. Curr Pharm Des 17: 1351-1358.
50. Wilson RI, Nicoll RA, (2002) Endocannabinoid signaling in the brain. Science 296: 678-682.
51. World Health Organization (1993) Composite International Diagnostic Interview: Core Version 1.1. Geneva, Switzerland: World Health Organization.
52. Zangen A, Solinas M, Ikemoto S, Goldberg SR, Wise RA, (2006) Two brain sites for cannabinoid reward. J Neurosci 26: 4901-4907.